or Try an Advanced Search...

    Technical Analysis for JSPR - Jasper Therapeutics, Inc

    Grade Last Price % Change Price Change
    D 22.03 -0.36% -0.08
    JSPR closed down 0.36 percent on Wednesday, April 24, 2024, on 42 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    Earnings due: May 10
    *** please verify all earnings dates ***
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Down Down
    Historical JSPR trend table...
    Date Alert Name Type % Chg
    NR7 Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    50 DMA Resistance Bearish -0.36%
    Shooting Star Candlestick Bearish -0.36%
    Doji - Bearish? Reversal -0.36%
    Lower Bollinger Band Walk Weakness -0.36%
    Wide Bands Range Expansion -0.36%
    Oversold Stochastic Weakness -0.36%
    Lower Bollinger Band Walk Weakness -2.18%
    Older End-of-Day Signals for JSPR ...

       Recent Intraday Alerts

    Alert Time
    Up 2% about 18 hours ago
    Up 1% about 18 hours ago
    Possible NR7 about 18 hours ago
    60 Minute Opening Range Breakout about 19 hours ago
    60 Minute Opening Range Breakdown about 21 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    JSPR Chart by TradingView
    Basic chart:

    Profile

    Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company develops JSP191, a humanized monoclonal antibody for clearing hematopoietic stem cells from bone marrow in patients undergoing a hematopoietic cell transplantation. It also develops Jasper eHSC Platform to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Life Sciences Biology Stem Cell Gene Therapy Transplantation Bone Marrow Hematopoietic Stem Cell

    Is JSPR a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Mar 28 RBC starts Jasper Therapeutics at outperform, cites market opportunity
    Mar 21 Jasper Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
    Mar 19 Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria
    Mar 15 New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia
    Mar 4 Jasper Therapeutics GAAP EPS of -$1.50 beats by $0.20
    Mar 4 Jasper Therapeutics Reports Fiscal 2023 Financial Results and Recent Corporate Developments
    Feb 26 Jasper Therapeutics to Present at the 43rd Annual TD Cowen Healthcare Conference
    Feb 23 Jasper Therapeutics Presents Data from Preclinical Briquilimab Studies at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
    Feb 12 Over $15M Bet On Aon? Check Out These 3 Stocks Insiders Are Buying
    Feb 7 Jasper Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Conference
    See more JSPR news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 31.01
    52 Week Low 4.0
    Average Volume 107,023
    200-Day Moving Average 13.38
    50-Day Moving Average 24.65
    20-Day Moving Average 26.34
    10-Day Moving Average 24.26
    Average True Range 1.98
    RSI (14) 37.89
    ADX 29.38
    +DI 16.53
    -DI 28.37
    Chandelier Exit (Long, 3 ATRs) 25.07
    Chandelier Exit (Short, 3 ATRs) 27.28
    Upper Bollinger Bands 32.03
    Lower Bollinger Band 20.66
    Percent B (%b) 0.12
    BandWidth 43.14
    MACD Line -0.82
    MACD Signal Line 0.10
    MACD Histogram -0.9163
    Fundamentals Value
    Market Cap 331.72 Million
    Num Shares 15.1 Million
    EPS -8.30
    Price-to-Earnings (P/E) Ratio -2.65
    Price-to-Sales 0.00
    Price-to-Book 2.78
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 23.75
    Resistance 3 (R3) 23.73 23.14 23.47
    Resistance 2 (R2) 23.14 22.70 23.15 23.37
    Resistance 1 (R1) 22.59 22.43 22.86 22.60 23.27
    Pivot Point 21.99 21.99 22.13 22.00 21.99
    Support 1 (S1) 21.44 21.56 21.72 21.46 20.79
    Support 2 (S2) 20.85 21.28 20.85 20.69
    Support 3 (S3) 20.29 20.85 20.59
    Support 4 (S4) 20.31